<DOC>
	<DOC>NCT00626080</DOC>
	<brief_summary>The aim of this study is to test the hypothesis that subcutaneous administration of insulin detemir, as compared to insulin NPH, leads to a more pronounced effect on cerebral glucose metabolism and/or cerebral blood flow in brain regions associated with appetite regulation, to account for the reported difference in weight.</brief_summary>
	<brief_title>Insulin Detemir Action in Cerebro</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Isophane insulin, beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Isophane Insulin, Human</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Type 1 diabetic patients; Diabetes duration =/&gt; 1 year; HbA1c ~ 7,5%; Recent onset of DM; BMI &lt; 18 OR &gt; 35 kg/m2; T2DM; History of major heart/renal disease; Severe untreated proliferative retinopathy; History of recurrent severe hypoglycaemia; (History of) brain disorders; Alcohol abuse,(History of) drug abuse, benzodiazepines, selective betablockers, oral steroids, oral anticoagulants; Current psychiatric disease/treatment; (history of) eating disorders; History of severe head trauma accompanied by loss of consciousness; Any endocrine disease not well controlled for at least 3 months; Inability to undergo MRI; Visual acuity &lt; 0.3; Known or suspected allergy to trial product or related products</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Insulin</keyword>
	<keyword>Detemir</keyword>
	<keyword>Brain</keyword>
	<keyword>Glucose metabolism</keyword>
</DOC>